Table 2.

Overall Survival by FGFR1 amplification

FGFR1 status	Events/ Total	Median OS (years) (95% CI)	Log rank p
Entire cohort
amplified not amplified	8/37 45/189	5.9 (2.7 – NR) 4.6 (3.7 – 6.0)	0.36
Stage I–II
amplified not amplified	7/27 24/128	4.9 (2.7-NR) 5.6 (3.8-NR)	0.66
Stage III–IV
amplified not amplified	1/10 21/61	NR 2.5 (1.3–4.6)	0.07
Platinum chemoRT/chemo
amplified not amplified	0/4 11/25	NR 1.0 (0.7 – 4.3)	0.09

NR = not reached